Tag - DERM

Markets

Cantor starts Journey Medical at OW; PT $9

Cantor Fitzgerald initiated coverage of Journey Medical (NASDAQ:DERM) with an “overweight” rating and a 12-month price target of $9. The stock finished at $5.07 on Feb. 24. Journey is building a portfolio of commercial...

February 25, 2022

Developments

Dermira atopic dermatitis drug gets FDA fast track designation

Dermira’s (NASDAQ:DERM) lebrikizumab received FDA fast track designation for the treatment of moderate-to-severe atopic dermatitis. Lebrikizumab is a humanized monoclonal antibody that targets interleukin-13, which is...

December 10, 2019

Developments

Dermira atopic dermatitis drug meets primary endpoint in Phase 2b study

Dermira’s (NASDAQ:DERM) Phase 2b dose-ranging study of lebrikizumab in atopic dermatitis demonstrated that all three doses achieved greater improvements in the Eczema Area and Severity Index score, compared with placebo...

March 19, 2019

Tag - DERM

Cantor starts Journey Medical at OW; PT $9

Dermira atopic dermatitis drug gets FDA fast track designation

Dermira atopic dermatitis drug meets primary endpoint in Phase 2b study

General

More